A proliferation-inducing ligand enhances the anti-tumor effect of BCMA CAR T-cell through inhibition of soluble BCMA.
Adding a specific immune signal to CAR T cells helps them reach cancer cells hiding behind soluble tumor markers in myeloma.
This BBA Molecular Basis of Disease study demonstrates that APRIL, a BCMA ligand, inhibits soluble BCMA shedding from myeloma cells, thereby enhancing BCMA CAR T-cell access to membrane BCMA and improving anti-tumor activity. This strategy provides a preclinical rationale for combining APRIL with BCMA CAR T therapy to overcome soluble BCMA-mediated resistance in relapsed/refractory multiple myeloma.
What the study was
- Study design
- Preclinical experimental study
- Population
- Multiple myeloma cell lines and murine models
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Biochimica et biophysica acta. Molecular basis of disease
Why it surfaced
BBA Mol Basis Dis; APRIL+BCMA CAR T addresses soluble BCMA resistance; mechanistically relevant to current clinical challenges with ciltacabtagene/idecabtagene.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.